GLP1R and inflammatory bowel disease: A study demonstrated that IBD patients had deregulated expression of GLP-1R, chemokine ligand 20 (CCL20), and IL-33 in colon, and this was reversed by the treatment of GLP-1R agonists that led to reduced colonic inflammation [59].